OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial

OncoSil Medical (ASX:OSL) treated two more patients in the Netherlands using its implantable pancreatic cancer device, according to an April 17 filing with the Australian bourse. The treatment is part

MT NewswiresApr 17 18:52 ET

OncoSil Medical Treats First Commercial Patient in Turkey With Implantable Pancreatic Cancer Device

OncoSil Medical (ASX:OSL) treated the first commercial patient in Turkey with its implantable OncoSil pancreatic cancer therapy device, according to a Tuesday filing with the Australian Securities Exc

MT NewswiresApr 15 20:53 ET

OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study

OncoSil Medical (ASX:OSL) on Friday announced the first patient treatment in the UK that utilized its pancreatic cancer device for its TRIPP-FXX clinical study. The study aims to assess the safety and

MT NewswiresApr 11 23:29 ET

OncoSil Medical Obtains Device Reimbursement Approval in UK

OncoSil Medical (ASX:OSL) announced on Tuesday that its device can now be reimbursed at Imperial College Healthcare NHS Trust following an agreement with a large private insurance company in the UK, a

MT NewswiresApr 8 22:19 ET

First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device

OncoSil Medical (ASX:OSL) has penetrated another European market as two Austria-based patients received treatment using the OncoSil device for pancreatic cancer, according to a Friday filing with the

MT NewswiresApr 4 18:52 ET

Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer

Oncosil Medical (ASX:OSL) secured commitments to raise up to a total of AU$7.1 million via a placement to "sophisticated and professional investors" and a non-renounceable entitlement offer. The pancr

MT NewswiresMar 19 23:02 ET